Cerenome Posts First $0.7M Diagnostic Revenue but Cash Drops to $4.9M
CNSY has more than doubled off its 52-week low of $0.429 on elevated volume (10× avg).
Summary
Cerenome booked its first $0.7 million of net diagnostic revenue in Q3 2026 on roughly $1.55 million in gross billings at list prices, but the net loss widened to $8.7 million, or $1.14 per share, from $4.4 million a year earlier. Cash, cash equivalents and investments fell to $4.9 million from $8.6 million at June 30, and the balance sheet shows negative stockholders' equity of about $0.9 million — the going-concern warning stands. The company raised $3.8 million under its Equity Distribution Agreement after quarter end and closed a senior secured facility of up to $20 million with 3i, LP in September, so near-term funding is thin relative to a $7.5 million quarterly operating loss. Commercial progress is real: payer contracts now cover roughly 190 million lives, about 80% of U.S. private payers, with the Aetna national agreement effective November 1, and Medicare reimbursement is targeted for the first half of 2027. On the therapeutics side, the first 10 patients in the ReSPECT-LM multi-dose study showed no dose-limiting toxicities, and Phase 2 ReSPECT-GBM enrollment finished in October with topline data expected mid-2027. The November 16, 8:30 a.m. ET call will be the first chance for management to address the cash runway.
At the time of this announcement, CNSY was trading at $0.96 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $7.2M. The 52-week trading range was $0.43 to $18.89. This news item was assessed with negative market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.